Prometheon Pharma Completes Pilot Study of Insulin Patch in Mini-Pigs

Prometheon's large animal pilot study of their needle-free insulin TruePatch™ has been completed and is expected to be included for publication in an international peer-reviewed diabetes journal before the end of Q4. Early results of testing completed in August 2016 had already confirmed that Prometheon's extended-wear basal insulin patch works to lower blood glucose levels in a type 1 diabetic mini-pig model. Dr. Stephen Hsu (CEO/CSO) designed the clinical trial to compare patch vs. subcutaneous needle injection delivery of the long-acting (basal) insulin analogue called glargine (LANTUS®, BASALIN®). Glargine for administration by injection will soon be available as a biosimilar from several other global generics manufacturers. 

Follow us on Twitter (#PatchOnPig) and Face Book